Skip to content
Aton
EN
FR
EN
FR
Home
About Us
Our Strategy
Our Platforms
Open menu
Our Platforms
Preclinical & Clinical Services
Monoclonal Antibodies Production
Laboratory Equipment Production
Human Tissue Provision
Insights & News
Contact Us
Investors
Newsletter Signup
Minutes of the General Meeting of 21 december 2023
Update on the Group’s situation
Financial results – Semester 1, 2023
Aton strengthens its financial resources by issuing a €1.5m convertible bond with Vatel Capital
Stemcis expands its international horizons with the opening of a subsidiary in the United States
Hybrigenics re-brand to ‘Aton’
Minutes General Meeting – 28 June 2023
Visioconference May 4, 2023
Notice of Annual General Meeting
Annual results 2022